JP2017514847A - 突然変異ｒａｓペプチド及び化学療法剤を含むペプチドワクチン - Google Patents

突然変異ｒａｓペプチド及び化学療法剤を含むペプチドワクチン Download PDF

Info

Publication number
JP2017514847A
JP2017514847A JP2016565676A JP2016565676A JP2017514847A JP 2017514847 A JP2017514847 A JP 2017514847A JP 2016565676 A JP2016565676 A JP 2016565676A JP 2016565676 A JP2016565676 A JP 2016565676A JP 2017514847 A JP2017514847 A JP 2017514847A
Authority
JP
Japan
Prior art keywords
peptide
mutation
seq
chemotherapeutic agent
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016565676A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017514847A5 (enExample
Inventor
ヨン アムンド エリクセン
ヨン アムンド エリクセン
グスタヴ ガウデルナック
グスタヴ ガウデルナック
Original Assignee
タルゴバックス エーエスエー
タルゴバックス エーエスエー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50679896&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2017514847(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by タルゴバックス エーエスエー, タルゴバックス エーエスエー filed Critical タルゴバックス エーエスエー
Publication of JP2017514847A publication Critical patent/JP2017514847A/ja
Publication of JP2017514847A5 publication Critical patent/JP2017514847A5/ja
Priority to JP2020032081A priority Critical patent/JP7304629B2/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001164—GTPases, e.g. Ras or Rho
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2016565676A 2014-05-06 2015-05-05 突然変異ｒａｓペプチド及び化学療法剤を含むペプチドワクチン Pending JP2017514847A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2020032081A JP7304629B2 (ja) 2014-05-06 2020-02-27 突然変異ｒａｓペプチド及び化学療法剤を含むペプチドワクチン

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14167265.9 2014-05-06
EP14167265 2014-05-06
PCT/EP2015/059861 WO2015169804A1 (en) 2014-05-06 2015-05-05 Peptide vaccine comprising mutant ras peptide and chemotherapeutic agent

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020032081A Division JP7304629B2 (ja) 2014-05-06 2020-02-27 突然変異ｒａｓペプチド及び化学療法剤を含むペプチドワクチン

Publications (2)

Publication Number Publication Date
JP2017514847A true JP2017514847A (ja) 2017-06-08
JP2017514847A5 JP2017514847A5 (enExample) 2018-06-14

Family

ID=50679896

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016565676A Pending JP2017514847A (ja) 2014-05-06 2015-05-05 突然変異ｒａｓペプチド及び化学療法剤を含むペプチドワクチン
JP2020032081A Active JP7304629B2 (ja) 2014-05-06 2020-02-27 突然変異ｒａｓペプチド及び化学療法剤を含むペプチドワクチン

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020032081A Active JP7304629B2 (ja) 2014-05-06 2020-02-27 突然変異ｒａｓペプチド及び化学療法剤を含むペプチドワクチン

Country Status (16)

Country Link
US (1) US9757439B2 (enExample)
EP (1) EP3140320B1 (enExample)
JP (2) JP2017514847A (enExample)
KR (1) KR20170002563A (enExample)
CN (1) CN106414493A (enExample)
AU (1) AU2015257774B2 (enExample)
BR (1) BR112016025764A2 (enExample)
CA (1) CA2947963A1 (enExample)
CL (1) CL2016002794A1 (enExample)
DK (1) DK3140320T3 (enExample)
ES (1) ES2716923T3 (enExample)
IL (1) IL248671B (enExample)
MX (1) MX2016014414A (enExample)
RU (1) RU2700929C2 (enExample)
SG (2) SG11201608712PA (enExample)
WO (1) WO2015169804A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022536695A (ja) * 2019-06-12 2022-08-18 ビオンテック ユーエス インコーポレイテッド 新抗原組成物およびその使用
JP2023535982A (ja) * 2020-07-29 2023-08-22 スクイーズ バイオテクノロジーズ カンパニー 無核細胞を使用して変異型Ｒａｓに対する免疫応答を刺激する方法
JP2023550515A (ja) * 2020-11-24 2023-12-01 シャンハイ、ケンパーソー、バイオテクノロジー、カンパニー、リミテッド Ｒａｓ突然変異体エピトープペプチドおよびｒａｓ突然変異体を認識するｔ細胞受容体

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9775892B2 (en) 2013-12-09 2017-10-03 Targovax Asa Peptide mixture
RU2765874C2 (ru) 2016-10-26 2022-02-04 МОДЕРНАТиЭкс, ИНК. Матричные рибонуклеиновые кислоты для усиления иммунных ответов и способы их применения
EP3576780A1 (en) * 2017-02-01 2019-12-11 Modernatx, Inc. Immunomodulatory therapeutic mrna compositions encoding activating oncogene mutation peptides
CN110709094A (zh) 2017-02-03 2020-01-17 威斯康星州医药大学股份有限公司 Kras肽疫苗组合物及其使用方法
CA3103983A1 (en) 2018-06-19 2019-12-26 Biontech Us Inc. Neoantigens and uses thereof
WO2020002650A1 (en) 2018-06-29 2020-01-02 Targovax Asa A formulation
CN109550044B (zh) * 2018-10-19 2022-05-03 杭州纽安津生物科技有限公司 通用性多肽疫苗及其在制备治疗/预防胰腺癌药物中的应用
CN113416241B (zh) * 2020-04-09 2022-04-08 北京臻知医学科技有限责任公司 一种用于诱导肿瘤特异性免疫响应的通用型抗原肽库及试剂盒
JP2023535981A (ja) * 2020-07-29 2023-08-22 スクイーズ バイオテクノロジーズ カンパニー 有核細胞を使用して変異型Ｒａｓに対する免疫応答を刺激する方法
EP4423256A2 (en) * 2021-10-28 2024-09-04 Genentech, Inc. Systems and methods to identify mhc-associated antigens for therapeutic intervention
EP4522192A2 (en) * 2022-05-12 2025-03-19 The Johns Hopkins University Neoantigen vaccines for cancer prevention
WO2025103205A1 (en) * 2023-11-15 2025-05-22 Ck Life Sciences Development Limited Pharmaceutical compositions and methods for preventing or treating kras-associated diseases or conditions

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9103974D0 (en) 1991-02-26 1991-04-10 Norsk Hydro As Therapeutically useful peptides or peptide fragments
GB2328689A (en) 1997-08-27 1999-03-03 Norsk Hydro As Peptides based on the p21 ras proto-oncogene protein for the treatment of cancer
NO309798B1 (no) * 1999-04-30 2001-04-02 Targovax As Peptidblanding, samt farmasoytisk sammensetning og kreftvaksine som innbefatter peptidblandingen
AU2003301021C1 (en) 2002-12-16 2010-02-18 Globelmmune, Inc. Yeast-based vaccines as immunotherapy
US20140199405A1 (en) 2013-01-11 2014-07-17 Abraxis Bioscience, Llc Method for treating cancer based on mutation status of k-ras
US9775892B2 (en) 2013-12-09 2017-10-03 Targovax Asa Peptide mixture

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
ＢＲＩＴＩＳＨ ＪＯＵＲＮＡＬ ＯＦ ＣＡＮＣＥＲ, vol. 74, no. 11, JPN6019006155, 1996, pages 1828 - 1833, ISSN: 0004140371 *
ＥＵＲＯＰＥＡＮ ＪＯＵＲＮＡＬ ＯＦ ＣＡＮＣＥＲ, vol. [online], JPN6019006160, 6 March 2014 (2014-03-06), pages 10 - 1016, ISSN: 0004140376 *
ＩＮＴＥＲＮＡＴＩＯＮＡＬ ＪＯＵＲＮＡＬ ＯＦ ＣＡＮＣＥＲ, vol. 128, no. 5, JPN6019006154, 2011, pages 1120 - 1128, ISSN: 0004140370 *
ＩＮＴＥＲＮＡＴＩＯＮＡＬ ＪＯＵＲＮＡＬ ＯＦ ＣＡＮＣＥＲ, vol. 92, no. 3, JPN6019006157, 2001, pages 441 - 450, ISSN: 0004140373 *
ＪＯＵＲＮＡＬ ＯＦ ＧＡＳＴＲＯＥＮＴＥＲＯＬＯＧＹ ＡＮＤ ＨＥＰＡＴＯＬＯＧＹ, vol. 20, no. 1, JPN6019006161, 2005, pages 67 - 72, ISSN: 0004140377 *
ＪＯＵＲＮＡＬ ＯＦ ＭＯＬＥＣＵＬＡＲ ＭＥＤＩＣＩＮＥ, vol. 81, no. 1, JPN6019006156, 2003, pages 43 - 50, ISSN: 0004140372 *
ＲＡＤＩＯＴＨＥＲＡＰＹ ＡＮＤ ＯＮＣＯＬＯＧＹ, vol. 99, no. 2, JPN6019006159, 2011, pages 114 - 119, ISSN: 0004140375 *
日本消化器病学会雑誌, vol. 108, no. 12, JPN6019006158, 2011, pages 2003 - 2009, ISSN: 0004140374 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022536695A (ja) * 2019-06-12 2022-08-18 ビオンテック ユーエス インコーポレイテッド 新抗原組成物およびその使用
JP2023535982A (ja) * 2020-07-29 2023-08-22 スクイーズ バイオテクノロジーズ カンパニー 無核細胞を使用して変異型Ｒａｓに対する免疫応答を刺激する方法
JP2023550515A (ja) * 2020-11-24 2023-12-01 シャンハイ、ケンパーソー、バイオテクノロジー、カンパニー、リミテッド Ｒａｓ突然変異体エピトープペプチドおよびｒａｓ突然変異体を認識するｔ細胞受容体

Also Published As

Publication number Publication date
BR112016025764A2 (pt) 2018-01-16
JP2020100650A (ja) 2020-07-02
RU2016147527A3 (enExample) 2019-01-21
RU2700929C2 (ru) 2019-09-24
SG11201608712PA (en) 2016-11-29
JP7304629B2 (ja) 2023-07-07
CN106414493A (zh) 2017-02-15
ES2716923T3 (es) 2019-06-18
EP3140320B1 (en) 2018-12-26
CL2016002794A1 (es) 2017-06-09
MX2016014414A (es) 2017-02-23
AU2015257774A1 (en) 2016-12-22
WO2015169804A1 (en) 2015-11-12
IL248671A0 (en) 2017-01-31
IL248671B (en) 2021-08-31
EP3140320A1 (en) 2017-03-15
US20170065694A1 (en) 2017-03-09
RU2016147527A (ru) 2018-06-08
US9757439B2 (en) 2017-09-12
DK3140320T3 (en) 2019-04-15
AU2015257774B2 (en) 2018-12-20
KR20170002563A (ko) 2017-01-06
SG10201809701TA (en) 2018-12-28
CA2947963A1 (en) 2015-11-12

Similar Documents

Publication Publication Date Title
JP7304629B2 (ja) 突然変異ｒａｓペプチド及び化学療法剤を含むペプチドワクチン
JP7457642B2 (ja) タンパク質抗原およびその使用
JP2022535972A (ja) がん免疫療法の皮下投与のための組成物及び方法
KR20180129899A (ko) 신생항원 및 이것의 사용 방법
US9539299B2 (en) Combination therapy with WT1 peptide vaccine and temozolomide
JP2017501172A (ja) サバイビン指向性癌ワクチン治療
KR20220143812A (ko) B형 간염 바이러스와 관련된 질병의 치료
JP2024520477A (ja) ペプチドに基づくネオ抗原ワクチンの多成分化学組成物
US12059434B2 (en) Short-term activated DC1s and methods for their production and use
EP4378473A1 (en) Her2 vaccine composition
KR102624844B1 (ko) 암의 향상된 치료
US20250319172A1 (en) Anticancer vaccine composition comprising hsp90 antigenic peptide and use thereof
Cayssials et al. Beyond tyrosine kinase inhibitors: Combinations and other agents
US20230181633A1 (en) Methods of treating cancer using a combination of tumor membrane vesicles and metformin
JP2023512487A (ja) 癌を治療するための投与養生法および方法
HK1231899A1 (en) Peptide vaccine comprising mutant ras peptide and chemotherapeutic agent
HK1231899B (en) Peptide vaccine comprising mutant ras peptide and chemotherapeutic agent
US20250041278A1 (en) Tlr8 agonist for modulating immune response
US20250000971A1 (en) Tlr4 agonist for modulating immune response
WO2018088933A1 (en) Anti-tumor effects of a viral vector encoding a toll-like receptor and a toll-like receptor agonist
RU2773273C2 (ru) Неоантигены и способы их использования

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170328

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180420

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180420

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190226

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190524

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20191029